Patents by Inventor Manmohan Leleti

Manmohan Leleti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20080058341
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: May 22, 2007
    Publication date: March 6, 2008
    Inventors: Penglie Zhang, Andrew Pennell, John Wright, Wei Chen, Manmohan Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark Gleason, Yibin Zeng, Kevin Greenman
  • CXCR4 modulators
    Publication number: 20070275965
    Abstract: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.
    Type: Application
    Filed: March 30, 2007
    Publication date: November 29, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: William Thomas, Manmohan Leleti, Andrew Pennell
  • CXCR4 MODULATORS
    Publication number: 20070254915
    Abstract: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.
    Type: Application
    Filed: March 30, 2007
    Publication date: November 1, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Manmohan Leleti, William Thomas, Penglie Zhang, Andrew Pennell
  • Substituted dihydropyridines and methods of use
    Publication number: 20070112015
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.
    Type: Application
    Filed: October 30, 2006
    Publication date: May 17, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Clarence Hurt, Andrew Pennell, John Wright, Manmohan Leleti, Qiang Wang, William Thomas, Yandong Li, Dean Dragoli
  • Azaindazole compounds and methods of use
    Publication number: 20070010524
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Wei Chen, Manmohan Leleti, Yandong Li, Lianfa Li, Yuan Xu
  • Azaindazole compounds and methods of use
    Publication number: 20070010523
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Wei Chen, Manmohan Leleti, Matthew Ronsheim